Cell line · CVCL_0630
Papers49
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 49
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Circulating Tumour Cell GALNT13 Expression Is Associated with Prognosis and Treatment Response in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ZUP1 contributes to cisplatin resistance and treg-related signaling in non-small cell lung cancer. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Silencing of BCAT1 induces ferroptosis and inhibits brain metastasis of non-small cell lung cancer via activating the cGAS-STING pathway. | J Thorac Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. | Immunity | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HNRNPA2B1 confers immune escape of non-small cell lung cancer through targeting lactate/ferroptosis. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the anticancer potential of green synthesized Zn/Cu nanocomposites from olive leaves against lung cancer. | Hereditas | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| High NHLRC2 expression is associated with shortened survival in lung adenocarcinoma. | Transl Lung Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin. | Cancer Discov | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0630/papers